Company Overview and News

5
Is iShares Edge MSCI Multifactor Emerging Markets ETF (EMGF) a Hot ETF Right Now?

2018-09-18 zacks
Designed to provide broad exposure to the Broad Emerging Market ETFs category of the market, the iShares Edge MSCI Multifactor Emerging Markets ETF (EMGF - Free Report) is a smart beta exchange traded fund launched on 12/08/2015.
EMGF HXSCF IEMG MDPEB 0700 INDA MDP VWO HXSCL

1
Stocks Rebounded Last Week As U.S. Bonds, Commodities Fell

2018-09-18 seekingalpha
US and foreign stock markets firmed up last week, including the recently pummeled slice of emerging-markets equities, based on a set of exchange-traded products. Meanwhile, US investment-grade bonds and broadly defined commodities posted the only setbacks for the major asset classes over the five trading days through September 14.
VEA VWO

 
Is SPDR S&P Emerging Markets Dividend ETF (EDIV) a Hot ETF Right Now?

2018-09-13 zacks
The SPDR S&P Emerging Markets Dividend ETF (EDIV - Free Report) made its debut on 02/23/2011, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the market.
0941 EDIV VODAF CHLKF CHL VDMCY IEMG VWO

10
Is iShares Emerging Markets Dividend ETF (DVYE) a Hot ETF Right Now?

2018-09-11 zacks
The iShares Emerging Markets Dividend ETF (DVYE - Free Report) made its debut on 02/23/2012, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the market.
DVYE SSW IEMG SSWN VWO SSWA

 
Across-The-Board Losses For The Major Asset Classes Last Week

2018-09-11 seekingalpha
Selling weighed on all the main categories of global markets last week, based on a set of exchange-traded products. The biggest slide: stocks in emerging markets.
VWO

9
Interactive Brokers - Strong U.S. Labor Market May Signal More Suffering For Emerging Market Corporates

2018-09-10 seekingalpha
While August nonfarm payrolls provided further evidence of a strong U.S. labor market, any ensuing optimism about the domestic economy may spur more pain for emerging markets.
ACH TRI CI VWO

11
Movado Group, Ethan Allen Interiors, Vanguard FTSE Emerging Markets and iShares Core MSCI Emerging Markets highlighted as Zacks Bull and Bear of the Day

2018-09-05 zacks
Chicago, IL – September 5, 2018 – Zacks Equity Research highlights Movado Group (MOV - Free Report) as the Bull of the Day, Ethan Allen Interiors (ETH - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onVanguard FTSE Emerging Markets ETF (VWO - Free Report) and iShares Core MSCI Emerging Markets ETF (IEMG - Free Report) .
MOV HLX MACK ATH IEMG BOSSY MOVAA WTW ETH RUSHA RUSHB HII HUGPF ADVM AMWD VWO SOI

 
Ivy Portfolio September Update

2018-09-05 seekingalpha
The Ivy Portfolio spreadsheet tracks the 10-month moving average signals for two portfolios listed in Mebane Faber's book, The Ivy Portfolio: How to Invest Like the Top Endowments and Avoid Bear Markets. Faber discusses 5-, 10-, and 20-security portfolios that have trading signals based on long-term moving averages.
RWX VEU VWO

 
The Emerging Markets Currency Crisis: What Investors Should Know

2018-09-04 zacks
As the U.S. dollar rallies, other nations, especially those with emerging markets, are suffering from weakening currencies against the benchmark. Starting with the crash of the Turkish lira a few weeks ago, the Mexican peso, Argentinean peso, South African rand, and Indonesian rupiah have all crashed in a very short span of time.
IEMG VWO

 
Is iShares Edge MSCI Multifactor Emerging Markets ETF (EMGF) a Hot ETF Right Now?

2018-08-23 zacks
The iShares Edge MSCI Multifactor Emerging Markets ETF (EMGF - Free Report) made its debut on 12/08/2015, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the market.
EMGF HXSCF IEMG 0700 INDA VWO HXSCL

 
Is SPDR S&P Emerging Markets Dividend ETF (EDIV) a Hot ETF Right Now?

2018-08-21 zacks
A smart beta exchange traded fund, the SPDR S&P Emerging Markets Dividend ETF (EDIV - Free Report) debuted on 02/23/2011, and offers broad exposure to the Broad Emerging Market ETFs category of the market.
EDIV VODAF VDMCY IEMG MLNX VWO

11
Is iShares Emerging Markets Dividend ETF (DVYE) a Hot ETF Right Now?

2018-08-14 zacks - 1
Making its debut on 02/23/2012, smart beta exchange traded fund iShares Emerging Markets Dividend ETF (DVYE - Free Report) provides investors broad exposure to the Broad Emerging Market ETFs category of the market.
SSW IEMG SSWN DVYE CSX VWO SSWA

 
Turkey Tumbles, Financial Markets Are Unnerved

2018-08-14 seekingalpha
The Turkish lira is down more than 40% year to date, with Friday's fall alone reaching 18.5% at one point and ending down 14.3% for the day. While Turkey's economy is not large, some major European banks have big exposures in non-lira loans. The European Central Bank is reported to be concerned about the vulnerability of such banks, in particular, BBVA, UniCredit (OTCPK:UNCFF) and BNP (OTCQX:BNPQF).
TUR EWG EZU VWO

 
Emerging Markets And Developed Markets (Ex-U.S.): Setting Up For An Attractive Entry Point?

2018-08-12 seekingalpha
One of the classic scenes from Braveheart was when Mel Gibson, playing William Wallace, was standing in the field facing down the English cavalry, and holding back his troops, yells, "Hold!… Hold!… Hold!" waiting until the heavy horses and opposition were nearly right on top of them, before unleashing his armaments.
VWO EEM

7
The Top 11 India ETFs - Accessing The World's Fastest Growing Large Market

2018-08-11 seekingalpha
Of the five largest global economies (abbreviated "JUICE"), India remains the most difficult for foreigners to access, except via ETFs or futures.
500325 RELIANCE IBKR HINDUNILVR TTNQY S68 532540 RIGD 500696 HDFCBANK 500570 TATAMOTORS VWO RLNIY SPXCF IBN INFY SPXCY WIT ICICIBANK HDB 532174 500180 TCS TTM

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 922042858